Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 plus BP102 and XELOX in first-line advanced colorectal cancer
CTR20210880Phase 3Terminated
- Sponsor
- Suzhou Sundia Biotech Co., Ltd.
- Start
- Apr 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of retlirafusp alfa in colorectal cancer (CRC), sponsored by Suzhou Sundia Biotech Co., Ltd.. Started Apr 2021; status: terminated.
02
Drugs
retlirafusp alfa
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20210880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210880.